Frontier IP sees maturity spread across portfolio companies

0
14

() portfolio company Exscientia has signed a US$70mln collaboration with the Bill & Melinda Gates Foundation to develop anti-viral therapeutics against coronavirus and other pandemic viruses.

The four-year agreement will fund work into small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches, Exscientia said in a statement.

Exscientia will use its technology platform and in-house expertise to discover and develop five phase 1-ready assets with the Gates Foundation to provide knowledge in antivirals and global public health

The collaboration will initially focus on developing broad-spectrum Coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead program, which targets the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19.

LEAVE A REPLY

Please enter your comment!
Please enter your name here